3Yu YS,Zhou WL,Chen YG,et al.Epidemiological and antibiotic resistant study on extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Zhejiang Province.Chin Med J,2002,115:1479-1482.
7Paterson DL,Mulazimoglu L,Casellas JM,et al.Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteremia.Clin Infect Dis,2000,30:473-478.
8Yu WL,Jones RN,Hollis RJ,et al.Molecular epidemiology of extended-spectrum β-lactamase producing,fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan.J Clin Microbiol,2002,40:4666-4669.
10Bedenic B,Beader N,Zagar Z.Effect of inoculum size on the antibacterial activity of cefpirome and cefepime against Klebsiella pneumoniae strains producing SHV extended spectrum beta-lactamases.Clin Microbiol Infect,2001,7:626-635.
7Livermore DM, Williams JD. β-lactams: mode of action and mechanisms of bacterial resistance. In: Lorian V, eds. Antibiotics in laboratory medicine. 4th ed. Baltimore:Williams & Wilkins, 1996. 502-578.
8Sanders CC. β-lactamase of gram negative bacteria: new challenges for new drugs. Clin Infect Dis, 1992,14:1089-1099.
9Naumiuk L, Samet A, Dziemaszkiewicz E. Cefepime in vitro activity against derepressed extended-spectrum β-lactamase(ESBL)-producing and non-ESBL-producing Enterobacter cloacae by a disc diffusion method. J Antimicrob Chemother, 2001,48:321-322.
10National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 9th informational supplement(M100-S9). Wayne:NCCLS,1999.
